Advertisement
Canada markets closed

  • S&P/TSX

    21,885.38
    +11.66 (+0.05%)
     

  • S&P 500

    5,048.42
    -23.21 (-0.46%)
     

  • DOW

    38,085.80
    -375.12 (-0.98%)
     

  • CAD/USD

    0.7321
    -0.0002 (-0.03%)
     

  • CRUDE OIL

    83.82
    +0.25 (+0.30%)
     

  • Bitcoin CAD

    87,985.90
    -13.16 (-0.01%)
     

  • CMC Crypto 200

    1,390.00
    +7.42 (+0.54%)
     

  • GOLD FUTURES

    2,345.50
    +3.00 (+0.13%)
     

  • RUSSELL 2000

    1,981.12
    -14.31 (-0.72%)
     

  • 10-Yr Bond

    4.7060
    +0.0540 (+1.16%)
     

  • NASDAQ futures

    17,781.25
    +213.75 (+1.22%)
     

  • VOLATILITY

    15.37
    -0.60 (-3.76%)
     

  • FTSE

    8,078.86
    +38.48 (+0.48%)
     

  • NIKKEI 225

    37,780.35
    +151.87 (+0.40%)
     

  • CAD/EUR

    0.6827
    +0.0006 (+0.09%)
     

Today's Research Reports on Trending Tickers: Evofem Biosciences and Diffusion Pharmaceuticals

ACCESSWIRE

NEW YORK, NY / ACCESSWIRE / December 18, 2018 / Evofem Biosciences had a day of gains on Monday after announcing positive results on its hormone free birth control gel. Shares of Diffusion Pharmaceuticals were in the red despite announcing that the company was awarded a patent for the use of its breakthrough drug, trans sodium crocetinate (TSC), in conjunction with Tissue Plasminogen Activator (tPA) for the treatment of stroke.

The Market Edge Initiates Coverage on:

Evofem Biosciences, Inc.
https://marketedgereport.com/report/EVFM/

Diffusion Pharmaceuticals Inc.
https://marketedgereport.com/report/DFFN/

ADVERTISEMENT

Evofem Biosciences, Inc. shares closed up 15.71% yesterday on skyrocket volume compared to usual. The stock traded nearly 5.4 million shares compared to volume of just under 41,000 shares. The shares however lost about 5% of these gains in after-hours trading. The company announced that its hormone-free birth control gel met the main goal in a late-stage study, bringing the first hormone-free contraceptive close to approval. "We are excited by these compelling study results, which solidify Amphora's position as the most substantial birth control innovation in nearly 20 years and a significant advancement for women and their sexual and reproductive health," said Saundra Pelletier, Chief Executive Officer of Evofem Biosciences. "We look forward to further data analysis and to submitting the Amphora NDA to the FDA in the second quarter of 2019. If approved, we plan to commercialize this first- in-class MVP-R for birth control in January 2020 to meet the needs of the 16.5 million women who are not using a contraceptive method but do not want to get pregnant, including women who cannot or will not use hormonal birth control methods.”

Access The Market Edge's Evofem Biosciences, Inc. Research Report:
https://marketedgereport.com/report/EVFM/

Diffusion Pharmaceuticals Inc. shares were down 1.40% at the close yesterday on nearly 7.4 million shares traded. The company announced that it has been awarded a patent for the use of its breakthrough drug, trans sodium crocetinate (TSC), in conjunction with Tissue Plasminogen Activator (tPA) for the treatment of stroke. “Nearly two million brain cells die each minute during a stroke, and TSC is a significant innovation in how patients receive care, given that it will potentially be the first and only front-line treatment,” said David Kalergis, Chairman and CEO of Diffusion. “Our company is committed to fighting life-threatening medical conditions, and there’s no doubt that stroke is a life-threatening and life-altering condition for families throughout our country and around the world. This patent is an extension of that commitment, as our research indicates that using TSC in conjunction with tPA – which remains the only FDA approved therapeutic for stroke – improves outcomes for patients.

Access The Market Edge's Diffusion Pharmaceuticals Inc. Research Report:
https://marketedgereport.com/report/DFFN/

Our Actionable Research on Evofem Biosciences, Inc. (NASDAQ: EVFM) and Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) can be downloaded free of charge at The Market Edge.

The Market Edge

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

The Market Edge has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of MarketEdgeReport.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. MarketEdgeReport.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.marketedgereport.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

The Market Edge, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@marketedgereport.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: MarketEdgeReport